ArticleFrontiers in bioinformatics2026
HVIface: sequence-based deep learning for decoding human-virus protein-protein interfaces.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Human-virus protein-protein interactions (PPIs) govern critical steps in viral entry, replication, and immune modulation. Despite their importance, the physicochemical determinants underlying human-virus interface recognition remain incompletely understood. A detailed characterization of these determinants is essential for uncovering viral hijacking mechanisms and enabling therapeutic targeting. To address this, we developed a sequence-based deep learning framework, HVIface, for residue-level prediction of human-virus PPI interfaces. Methods: HVIface was trained on a curated dataset of 73 structurally resolved human-virus complexes obtained from the Protein Data Bank. The model integrates 18 sequence-derived features, including residue contact potentials, physicochemical compatibility measures, and co-evolutionary signals. Performance was evaluated on an independent test set and compared against existing methods such as PIPENN and PeSTo. Additionally, feature importance analysis was conducted to identify key determinants contributing to interface prediction. Results: HVIface achieved an accuracy of 0.85 on the independent test set, outperforming existing approaches in identifying human-virus interface residues. Feature importance analysis highlighted environmentally weighted charge compatibility and co-evolution-derived contact potentials as dominant contributors. Case studies involving HIV-1 Integrase-Nup62, Influenza PB1-Nup85, and HCV NS5A-LASP1 complexes demonstrated that viral proteins preferentially target solvent-accessible, electrostatically favorable host regions through compact hotspot-driven architectures. Discussion: The findings reveal that electrostatic complementarity and localized residue clustering are central to viral-host interface formation, suggesting conserved physicochemical principles underlying viral targeting strategies. HVIface not only provides a robust predictive framework but also offers mechanistic insights into human-virus interface chemistry. These insights can facilitate systematic exploration of viral interactions and support the development of targeted therapeutic interventions. The source code is available at: https://github.com/krishnakantgupta-ai/HVIface_MMAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.